Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOSPIVAC: Tdap-IPV Vaccination Remedial Strategy in Patients >= 65 Years
NCT03587610Completed
- Sponsor
- Centre Hospitalier Le Mans
- Start
- May 2018
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine in Tetanus, diphtheria, pertussis and 1 more (2 arms), sponsored by Centre Hospitalier Le Mans. Primary endpoint: Change in immunization rate after a hospital centered remedial strategy for Tdap-IPV vaccination at 2 months. Started May 2018; status: completed.
02
Drugs
tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine
03
Conditions
Tetanusdiphtheriapertussispoliomyelitis
Beyond the preview
Go deeper on NCT03587610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587610.